Results from Cox regression models for T2DM− versus T2DM+
| HR unadjusted | P value | HR adjusted* | P value | |
| 3-point MACE | 1.78 (1.44 to 2.19) | <0.001 | 1.44 (1.09 to 1.92) | 0.012 |
| Vascular mortality | 2.17 (1.62 to 2.91) | <0.001 | 1.73 (1.15 to 2.60) | 0.008 |
| Stroke | 1.65 (1.13 to 2.40) | 0.009 | 1.20 (0.72 to 2.02) | 0.489 |
| MCI | 1.46 (1.03 to 2.06) | 0.034 | 1.27 (0.80 to 2.02) | 0.308 |
| All-cause mortality | 1.70 (1.42 to 2.03) | <0.001 | 1.29 (1.00 to 1.65) | 0.050 |
*Adjustments were made for age, gender, BMI, history of smoking, arterial hypertension, systolic blood pressure, LDL cholesterol, HDL cholesterol, HbA1c, eGFR, use of statins, ACE inhibitors/ATII RBA and aspirin/clopidogrel.
ACE, angiotensin converting enzyme; ATII RBA, ATII receptor blocking agents; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; MCI, myocardial infarction; 3-point MACE, major cardiovascular endpoint (including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke); T2DM, type 2 diabetes mellitus.